Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-03-01-2012
- Volume 24
- Issue 3
Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.
By Kashyap R. Wadekar, Mitali Bhalme, S. Srinivasa Rao, K. Vigneshwar Reddy, L. Sampath Kumar, E. Balasubrahmanyam
The public and the pharmaceutical industry are placing greater attention on impurities in drug as evidenced by the attention given to pharmaceutical impurities in books, journal articles, and national and international guidelines. The health implications of impurities can be significant because of their potential teratogenic, mutagenic, or carcinogenic effects. Controlling and monitoring impurities in APIs and finished drug products, therefore, is a crucial issue in drug development and manufacturing.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
over 13 years ago
News: Market Boom for Genericsover 13 years ago
Stepping Up the Fight Against Counterfeitsover 13 years ago
Parametric Release and Real-Time Release Testingover 13 years ago
Securing the Pharma Supply Chainover 13 years ago
CMOs Face a Kodak Momentover 13 years ago
Single-Use Redundant FiltrationNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
